Fosamax and Osteonecrosis of the Jaw: Scientific Evidence of Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Specific Clinical Vigilance

The legacy of general health and science information dissemination has long served as a foundation for public understanding of medical conditions and treatments. Within this tradition, broad educational efforts have aimed to clarify the benefits and risks associated with therapeutic interventions, fostering informed decision-making among patients and healthcare providers. This heritage of balanced, accessible communication now provides a critical framework for examining more specific clinical concerns that arise from widespread medication use. As the scope of health information has expanded, attention has increasingly turned to the long-term safety profiles of commonly prescribed drugs. One area of particular focus involves the relationship between bisphosphonate therapy, specifically Fosamax, and the development of osteonecrosis of the jaw. This condition, characterized by exposed bone in the oral cavity that fails to heal, has prompted rigorous investigation into potential causative links. The transition from general health education to this specialized inquiry reflects a natural progression in medical discourse, where population-level data and clinical observations converge to identify emerging risks. Within this context, the occupational exposure dimension becomes relevant. Healthcare professionals, particularly those in dental and surgical fields, may encounter patients with a history of Fosamax use and must assess the associated risks. This pivot from broad health literacy to specific clinical vigilance underscores the importance of translating general scientific evidence into practical, context-aware guidance for practitioners managing patient care.

Bridging General Knowledge to Fosamax-Specific Risks

Building on the foundation of general health education, this section focuses specifically on Fosamax (alendronate sodium), a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of Fosamax use has not been determined, and for patients at low risk for fracture, consideration of drug discontinuation after 3 to 5 years of use is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the maxillofacial region, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways Linking Fosamax to ONJ

The mechanistic pathways linking Fosamax to ONJ involve the drug's pharmacology as a bisphosphonate that inhibits bone resorption. Bisphosphonates like alendronate accumulate in bone tissue, particularly in areas of high bone turnover such as the jaw. Multiscale characterization of jawbone treated with osteoporosis therapeutic agents, including bisphosphonate (alendronate), has been conducted in estrogen-deficient rats to understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research provides comprehensive information that can help better understand how bisphosphonate treatment affects the jawbone at multiple scales, from tissue mineral density distribution to nanoindentation properties of the bone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077/). The jawbone's unique characteristics, such as its high remodeling rate and susceptibility to infection and trauma, may contribute to the development of ONJ in patients taking Fosamax.

Timeline, Clinical Evidence, and Causation Considerations

Regarding the timeline between exposure and documented harm, the time to onset of symptoms of ONJ varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping Fosamax, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label includes a specific section on Osteonecrosis of the Jaw, which describes the condition, associated risk factors, and clinical recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The warnings note that ONJ can occur spontaneously but is generally associated with dental procedures and infections, and that risk may increase with longer bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label also states that in placebo-controlled studies, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups, which may complicate the assessment of causation for individual patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For affected patients, causation-related considerations include the presence of known risk factors, duration of Fosamax use, and the timing of symptom onset relative to drug initiation. The label advises discontinuation of Fosamax if severe symptoms develop, and notes that most patients had relief after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The recurrence of symptoms upon rechallenge with bisphosphonates suggests a drug-related component in some patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The multiscale characterization of jawbone in animal models provides evidence that bisphosphonate treatment can alter jawbone properties, which may contribute to ONJ development (https://pubmed.ncbi.nlm.nih.gov/40345077/). In summary, the scientific evidence establishes a connection between Fosamax and ONJ through clinical reports, risk factor analysis, and mechanistic studies. The prescribing information includes warnings about this risk, but the variable onset and the similarity of symptom rates in placebo groups highlight the complexity of establishing causation in individual cases. Patients and healthcare providers should consider the balance of benefits and risks when using Fosamax, particularly in the context of dental health and duration of therapy.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is the scientific evidence connecting Fosamax to osteonecrosis of the jaw?

Scientific evidence includes clinical reports of ONJ in patients taking Fosamax, identification of risk factors such as invasive dental procedures and duration of bisphosphonate use, and mechanistic studies showing that bisphosphonates like alendronate accumulate in jawbone and alter its properties. The prescribing information for Fosamax includes warnings about ONJ, and animal models have demonstrated jawbone-specific changes that may contribute to ONJ development. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56) (https://pubmed.ncbi.nlm.nih.gov/40345077/)

How long after starting Fosamax can osteonecrosis of the jaw occur?

The time to onset of ONJ symptoms can vary from one day to several months after starting Fosamax. Most patients experience relief after stopping the drug, but some have recurrence of symptoms when rechallenged with the same or another bisphosphonate. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, dental implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures. The risk may increase with longer duration of bisphosphonate use. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1)

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.